Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life
| Autor: | Jessica Ares, Elias Delgado, Raul Rodriguez Escobedo, Laura Manjón, Cecilia Sanchez Ragnarson, Fernando García Urruzola, Pedro Pujante Alarcón, Edelmiro Luis Menendez Torre, Laura Cacho |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent endocrine system diseases Insulin Glargine 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Hypoglycemia Young Adult 03 medical and health sciences Hba1c level 0302 clinical medicine Internal medicine medicine Humans Hypoglycemic Agents In real life In patient Aged Retrospective Studies Aged 80 and over Glycated Hemoglobin Type 1 diabetes Dose-Response Relationship Drug Drug Substitution Insulin glargine business.industry Body Weight nutritional and metabolic diseases Middle Aged medicine.disease Diabetes Mellitus Type 1 Treatment Outcome Delayed-Action Preparations Metabolic control analysis business Life study Follow-Up Studies medicine.drug |
| Zdroj: | Endocrinología, Diabetes y Nutrición (English ed.). 66:210-216 |
| ISSN: | 2530-0180 |
| DOI: | 10.1016/j.endien.2018.09.002 |
| Popis: | Current treatment of type 1 diabetes mellitus (T1DM) does not always achieve metabolic control because, among other things, the ocurrence of hypoglycemic events associated to insulin use.A descriptive real life study of 247 T1DM patients, 55.5% male, aged 46.53 ± 16.23 years, and with a mean diabetes duration of 21.89 ± 11.99 years, who were switched from basal insulin glargine U100 to glargine U300. The primary endpoints were changes in Hba1c and number of hypoglycemic events, while secondary endpoints included changes in weight and insulin dose after 6 and 12 months.After one year, no changes were seen in HbA1c, but the proportion of patients with HbA1c values7.5% increased at 6 months (33.5 vs. 40.5%; P0.05) and remained stable during one year of follow-up. Hypoglycemic events significantly decreased after one year of treatment in patients with previous hypoglycemic events. No changes were seen in body weight. Total insulin dose (U/kg) increased 7.24% at 6 months of treatment and by 8.69% at one year, mainly due to basal insulin. No changes were seen between the doses given at 6 and 12 months. These changes were similar in the different metabolic control groups and in patients with or without hypoglycemia. This increase was not related with prior basal insulin dose, baseline HbA1c level, number of hypoglycemic events or baseline weight.Glargine U300 is a good basal insulin alternative to treat T1DM, improving metabolic control in patients with HbA1c levels7,5 and decreasing hypoglycemic events in patients with history of hypoglycemia without increasing body weight. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect